- Location
thrombocytopenia
"-
Elderly Kidney Cancer Patients Benefit From Sunitinib Therapy
Feb 27, 2014By Sara Freeman, medwireNews Reporter Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows. Median progression-free survival ...
Tags: PFS, mRCC, Advanced Age, IFN
-
Protalix BioTherapeutics Has Announced Initial Positive Results From Oral GCD
Oct 16, 2013Israeli pharmaceutical company Protalix BioTherapeutics has announced initial positive results from its Phase I clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), in patients with Gaucher disease. In the trial, oral ...
-
A Multiple-sclerosis Drug Was Approved for Sale in Europe on Tuesday
Sep 22, 2013A multiple-sclerosis drug that was at the center of Sanofi SA's SAN.FR +1.12% $20 billion takeover battle for Genzyme Corp. three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide. The ...
-
The FDA Has Approved The Use of Astellas Pharma US' Mycamine
Jun 26, 2013The FDA has approved the use of Astellas Pharma US' Mycamine (micafungin sodium) for injection to treat pediatric patients aged four months and more with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, ...
-
US FDA Has Approved Xofigo for The Treatment of Symptomatic Prostate Cancer Therapy
May 17, 2013The US FDA has approved Xofigo (radium Ra 223 dichloride) for the treatment of symptomatic late-stage (metastatic) castration-resistant prostate cancer spread to bones but not to other organs in men. The therapy is indicated for men whose ...
-
GSK Gained FDA Priority Review Status for The Supplemental New Drug Application
Dec 7, 2012GlaxoSmithKline (GSK), Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. ...
Tags: GlaxoSmithKline, GSK, promacta, thrombocytopenia
-
GSK Promacta Won FDA Approval as Thrombocytopenia Therapy in Chronic Hepatitis C Patients
Nov 20, 2012GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients. Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C ...
Tags: FDA approval, thrombocytopenia therapy, chronic hepatitis C
-
GlaxoSmithKline Submitted Regulatory Applications for Eltrombopag in US, Europe
Jun 4, 2012Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...
